{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/18/3314251/29489/en/AIM-ImmunoTech-Achieves-Clinical-Milestone-as-Final-Subject-Receives-First-Dose-in-Phase-2-DURIPANC-Study-in-Metastatic-Pancreatic-Cancer.html", "message": "News view counter 807163 successfully enlarged"}